- Home
- BMI vs KNSA Comparison
BMI vs KNSA Comparison
Compare BMI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMI | KNSA |
|---|---|---|
| Founded | 1905 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMI | KNSA |
|---|---|---|
| Price | $133.39 | $52.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $170.13 | $60.86 |
| AVG Volume (30 Days) | 400.6K | ★ 483.5K |
| Earning Date | 04-17-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | 13.24 | ★ 225.00 |
| EPS | ★ 0.93 | 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $5.97 | $37.48 |
| Revenue Next Year | $7.17 | $17.87 |
| P/E Ratio | ★ $141.65 | $192.19 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $112.09 | $26.27 |
| 52 Week High | $249.56 | $59.87 |
Technical Indicators
Market Signals| Indicator | BMI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 55.68 |
| Support Level | $114.45 | $40.67 |
| Resistance Level | $184.62 | $59.87 |
| Average True Range (ATR) | 4.43 | 1.92 |
| MACD | 1.24 | 0.19 |
| Stochastic Oscillator | 87.99 | 88.31 |
Price Performance
Historical ComparisonAbout BMI Badger Meter Inc.
Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has globalised operations, with the vast majority of revenue derived from the USA. The company is an innovator in flow measurement, water quality and control products, serving water utilities, municipalities and commercial and industrial customers world-wide.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.